For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| 99Tc-MDP | 15mg 99Tc-MDP were intravenously administered twice a week for 10 weeks, then once a week for 8 weeks, every two weeks for 22 weeks and monthly for another 3m. 99Tc-MDP: 99Tc-MDP, H20000218 | 0 | None | 0 | 70 | 0 | 70 | View |
| Fosamax | 70mg po every week for 12 months. Alendronate Sodium: H20080172 | 0 | None | 0 | 72 | 6 | 72 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| upper gastrointestinal (GI) adverse events | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |